New Test IDs Cancer Cells in Tumors
TOOLBOX   Resize
 Save/Share +
COMMENT
 Discussion Policy
 CLOSE
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
|
THURSDAY, July 31 (HealthDay News) -- A test that helps identify the type of cancer cells present in a tumor has been approved by the U.S. Food and Drug Administration.
The Pathwork Tissue of Origin test compares the genetic material of a patient's tumor with genetic data stored in a database from evaluated cancers. The test, which is able to analyze thousands of pieces of genetic material at a time, considers 15 common cancer types, including those of the bladder, breast, and colon.
"The clearance of the Pathwork test is another step in the continued integration of molecular-based medicine into standard practice," Dr. Daniel Schultz, director of the FDA's Center for Devices and Radiological Health, said in an agency news release.
The test and its technology are produced by Pathwork Diagnostics of Sunnyvale, Calif., and Affymetrix Inc., of Santa Clara, Calif.
More information
The FDA has more about this approval.
